MA-ABIOMED
Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support at Ascension St. John Hospital in Detroit, led the procedures. This single-arm, prospective, multi-center trial will evaluate the rate of major adverse cardiovascular and cerebrovascular events (MACCE) in adult patients who receive Impella ECP support during an elective or urgent high-risk percutaneous coronary intervention (PCI).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221221005143/en/
Impella ECP, the world's smallest heart pump, is placed percutaneously into the heart's left ventricle. (Graphic: Business Wire)
Impella ECP is the world’s smallest heart pump and the only heart pump compatible with small bore access and closure techniques. It is 9 Fr in diameter upon insertion and removal from the body. Once in the body, it expands and supports the heart’s pumping function, providing peak flows up to 5 L/min.
Both patients enrolled in the trial received Impella ECP support during challenging left main coronary bifurcation stent procedures involving heavily calcified lesions. After Impella ECP was removed, the first patient was closed with an 8 Fr closure device.
“The research and clinical teams at Ascension St. John are delighted about enrolling the first patients in the Impella ECP FDA Pivotal Trial,” said Dr. Kaki, who is national principal investigator of this study. ”Impella ECP advances the opportunity for physicians to provide critical hemodynamic support during high-risk PCI procedures by delivering similar or higher flow compared to other options through a smaller vascular sheath for access. This technology has the potential to improve patient safety and cath lab throughput because of the smaller arteriotomy required for pump placement.”
“Impella ECP demonstrates Abiomed’s leadership in technology and innovation as we have broken the small-bore barrier through the development of the world’s smallest heart pump,” said Mike Minogue, Abiomed’s Chairman, President and Chief Executive Officer. “At Abiomed, we remain committed to developing smaller, smarter and more connected technologies that will improve outcomes for patients with heart disease. I applaud the teams within the medical community and at Abiomed who helped us achieve this milestone.”
In June 2020, the FDA approved the Impella ECP early feasibility study (EFS). Fifty-four patients have been treated to date in the EFS, including some patients treated using the pivotal clinical trial protocol. Impella ECP received FDA breakthrough device designation in August 2021. This designation demonstrates that Impella ECP meets the FDA’s stringent requirements for a breakthrough device. The Impella ECP Pivotal Clinical Trial received FDA approval on March 2, 2022 and will enroll up to 217 patients in the U.S. Additional details about the pivotal trial are available here.
Impella ECP is an investigational device limited by federal law to investigational use only.
ABOUT ABIOMED
Based in Danvers, Massachusetts, USA, Abiomed (Nasdaq: ABMD) is a leading provider of medical technology that provides circulatory support and oxygenation. Our products are designed to enable the heart to rest and recover by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit abiomed.com.
FORWARD-LOOKING STATEMENTS
Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221221005143/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Svante Launches World's First Commercial Gigafactory for Carbon Capture & Removal Filters13.5.2025 22:50:00 CEST | Press release
This next-generation carbon capture and removal solution represents a generational leap forward for managing carbon emissions from industrial sectors such as pulp & paper, waste-to-energy, cement, steel, and energy. Svante Technologies Inc. (Svante), a global leader in carbon capture and removal technologies, has officially completed the commissioning of its new Centre of Excellence for Carbon Capture and Removal – Redwood manufacturing Facility (Redwood) in Burnaby, British Columbia. This milestone marks the launch of the world's first gigafactory dedicated to producing commercial-scale carbon capture and removal filters designed to trap CO2 directly from industrial emissions and the atmosphere, and with the mindset of high-volume automation and product standardization to lower the manufacturing cost. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513713072/en/ Claude Letourneau, President & CEO, Svante Group opens the S
Svante and SAMSUNG E&A Sign Joint Development Agreement to Offer Digitally Enabled Skid-Mounted Modular Carbon Capture Plants13.5.2025 22:46:00 CEST | Press release
Svante and SAMSUNG E&A have signed a joint development agreement to offer standardized skid-mounted modular carbon capture plants based on Svante’s novel VeloxoTherm™ solid sorbent-based carbon capture filter technology, leveraging SAMSUNG E&A’s advanced digital solutions and modularization capabilities. Standardized modular packages will be branded and marketed globally by Svante and SAMSUNG E&A to deliver commercial carbon capture, use, and storage projects from the early project development stage through to engineering, procurement, and fabrication (EPF) across the heavy industrial and energy sectors. Svante Technologies Inc. (Svante) and SAMSUNG E&A announced today that they have signed a joint development agreement to jointly develop a set of standardized skid-mounted modular carbon capture plants based on Svante’s novel VeloxoTherm solid sorbent-based carbon capture filter technology, leveraging SAMSUNG E&A’s advanced digital solutions and modularization capabilities. The agreeme
AWS and HUMAIN Announce Groundbreaking AI Zone to Accelerate AI Adoption in Saudi Arabia and Globally13.5.2025 18:09:00 CEST | Press release
More than $5 billion joint investment in AI infrastructure, AWS services, and AI training and talent development will advance Saudi Arabia’s mission to be a global leader in AI Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), and HUMAIN, Saudi Arabia’s newly created company responsible for driving AI innovation across the Kingdom and globally, today announced plans to invest $5 billion-plus in a strategic partnership to build a groundbreaking “AI Zone” in the Kingdom. This first-of-a-kind AI Zone will bring together multiple innovative capabilities, including dedicated AWS AI infrastructure and servers with world-class semiconductors, UltraCluster networks for faster AI training and inference, AWS services like SageMaker and Bedrock, and AI application services such as Amazon Q to advance Saudi Arabia’s mission to be a world leader in AI. AWS previously announced and is currently building an AWS infrastructure region in Saudi Arabia that will become availabl
Citco enters strategic partnership with GIC13.5.2025 17:05:00 CEST | Press release
The Citco group of companies (Citco) and GIC are pleased to announce that they have entered a long term, strategic relationship. As part of the relationship, GIC, a global institutional investor, has become a minority shareholder in Citco. The founding Smeets Family shall remain the majority shareholder in Citco. “Citco has organically grown into a global market-leading asset servicing business, delivering value to investors like GIC for over 50 years. Our investment aligns squarely with GIC’s commitment to building long-lasting partnerships that empower family-owned businesses to thrive. With a combination of client-centric solutions and savvy technological investments Citco is at the forefront of their industry. We look forward to partnering with Citco and the Smeets family as we embark on this new chapter together." – Girish Karira, Head of Integrated Strategies Group and Head, New York Office at GIC. “We look forward to continuing our strategic relationship with GIC. Their industry
Tigo Energy Resolves Multi-Year Patent Infringement Litigation With SMA13.5.2025 15:00:00 CEST | Press release
Settlement validates Tigo Intellectual Property, concludes IP litigation with SMA, and reinforces innovation in the marketplace. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced that it has reached a multi-year settlement with SMA (SMA Solar Technology AG and SMA Solar Technology America LLC) over litigation regarding the infringement of Tigo intellectual property by SMA. The settlement concludes the infringement complaint brought by Tigo on July 11, 2022, Case No. 1:22-cv-00915 (D. Del.) alleging infringement of certain patents by SMA. Terms of the settlement will remain undisclosed. According to National Electric Code § 690.12, “Rapid Shutdown of PV Systems on Buildings” requires that PV system circuits “installed on or in buildings shall include a rapid shutdown function to reduce shock hazard for emergency responders.” Tigo rapid shutdown technology is compliant with UL 1741, the Standard
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom